The genetic mechanisms that regulate neurodegeneration are only poorly understood. We show that the loss of one allele of the p53 family member, p73, makes mice susceptible to neurodegeneration as a consequence of aging or Alzheimer's disease (AD). Behavioral analyses demonstrated that old, but not young, p73 +/À mice displayed reduced motor and cognitive function, CNS atrophy, and neuronal degeneration. Unexpectedly, brains of aged p73 +/À mice demonstrated dramatic accumulations of phospho-tau (P-tau)-positive filaments. Moreover, when crossed to a mouse model of AD expressing a mutant amyloid precursor protein, brains of these mice showed neuronal degeneration and early and robust formation of tangle-like structures containing P-tau. The increase in P-tau was likely mediated by JNK; in p73 +/À neurons, the activity of the p73 target JNK was enhanced, and JNK regulated P-tau levels. Thus, p73 is essential for preventing neurodegeneration, and haploinsufficiency for p73 may be a susceptibility factor for AD and other neurodegenerative disorders.
INTRODUCTION
The cellular mechanisms that regulate nervous system degeneration during aging or in neurodegenerative disorders are only poorly understood, in spite of their clinical importance. For example, much of what we know regarding neural cell death comes from studies of naturally occurring developmental death or injury-induced death, but the relevance of these relatively well-understood apoptotic mechanisms to aging or neurodegeneration is still an open question (for example, see Dusart et al., 2006; Zhu et al., 2006) . Moreover, the pathology observed in many neurodegenerative disorders indicates that neurons accumulate intracellular protein aggregates and/or cellular damage that leads to their slow degeneration and death, as opposed to a rapid and controlled apoptotic suicide. Instead, increasing evidence indicates that, in the aged or degenerating nervous system, prolonged exposure to relatively minor insults leads to cumulative neuronal oxidative stress and/or DNA damage, which in turn causes neurons to senesce, reenter the cell cycle and/or atrophy, and ultimately degenerate (Lin and Beal, 2006; Herrup and Yang, 2007) . Thus, both the cause and the enactment of neuronal cell death differ during development versus aging or degeneration.
While many neurodegenerative disorders appear to be much more than just accelerated aging, several lines of evidence suggest some similarities. For example, overexpression in Drosophila motor neurons of SOD1, one gene that is mutated in familial amyotrophic lateral sclerosis (ALS), significantly extends fly lifespan (Parkes et al., 1998) . Moreover, brains of some aged, apparently normal individuals display neurodegenerative hallmarks such as P-PHF-tau neurofibrillary tangles (Imhof et al., 2007) . Thus, perturbations that accelerate neural aging may contribute to and/or predispose individuals to neurodegenerative disorders.
In this regard, the tumor suppressor p53 and its family member, p63, have been implicated in aging outside of the nervous system; mouse models with enhanced p53 activity display accelerated aging and decreased lifespan (Tyner et al., 2002; Lavigueur et al., 1989; Maier et al., 2004) , and aging is enhanced in p63 +/À mice . These phenotypes are thought to occur as a consequence of disruptions in p53 family-mediated regulation of genomic stability and cellular senescence, which in turn impact on cellular/organismic aging (reviewed in Papazoglu and Mills, 2007) . While aging phenotypes in these mice were nonneural, they raise the possibility that the third p53 family member, p73, which is enriched in the PNS and CNS Pozniak et al., 2000) , might play an analogous role in the nervous system. However, although we previously showed that p73 is predominantly expressed as a truncated, dominant-inhibitory isoform, DNp73, that prevents neuronal apoptosis during development and following injury (Pozniak et al., 2000 (Pozniak et al., , 2002 Walsh et al., 2004) , there is no evidence to suggest that p73 is important for cellular necrosis or degeneration. Nonetheless, two recent reports indicate that decreased p73 expression occurs in some cases of AD (Li et al., 2004) and that some individuals have lost one copy of the genomic locus encompassing the p73 gene (Wong et al., 2007) . Here, we have asked whether p73 might play a previously unsuspected role in neurodegeneration and show that haploinsufficiency for p73 causes age-related neurodegeneration. Moreover, we demonstrate that decreased p73 causes formation of P-PHF-tau tangle-like structures in the aged nervous system, and coincident with the formation of amyloid plaques in an amyloid-based mouse model for AD. Thus, p73 is essential to prevent neurodegeneration during aging, and heterozygosity for p73 may be a susceptibility factor for AD or other neurodegenerative disorders.
RESULTS

Normal Levels of p73 Are Essential to Prevent
Behavioral Changes Indicative of Age-Related Neurodegeneration To ask whether changes in p73 copy number would sensitize mice to neurodegeneration, we compared the behavior of young (3-to 4-month-old) and aged (16-to 18-month-old) p73 +/À versus p73 +/+ mice. Initially, we examined an abnormal clasping behavior seen in several mouse neurodegeneration models (Liou et al., 2003; Lewis et al., 2000) , where mice clasp their limbs into their bodies when picked up by their tails. Aged p73 +/À but not p73 +/+ adults displayed this abnormal clasping behavior ( Figure 1A and Movie S1 available online (H) Absolute number of primary motor cortex neurons in p73 +/+ and p73 +/À brains as determined using the optical fractionator method. (*p < 0.05, n = 3 per group).
(I) Absolute number of glial cells in the primary motor cortex of p73 +/+ and p73 +/À brains as determined using the optical fractionator method (n = 3 per group).
(J) Representative photomicrograph of a Nissl-stained section through the p73 +/+ motor cortex showing condensed cells (arrow).
(K) Mean density of small, condensed cells in the motor cortex of young and aged p73 +/+ and p73 +/À brains (*p < 0.05, n = 5 per group).
mice were normal but acquired this behavior with time, so that almost 75% were positive by 16-18 months of age ( Figure 1B Figures 1D and 1E ), although the distance they traveled was similar ( Figure 1F ), suggesting a reduction in overall anxiety levels.
Since spatial learning and memory are also perturbed in mouse models of neurodegeneration, we asked whether aged p73 +/À mice were impaired in this regard using the hidden platform version of the Morris water maze (Kobayashi and Chen, 2005) . In this test, an invisible escape platform is submerged just below water level, and white curtains are marked with distinct cues, thereby allowing mice to triangulate the hidden platform location. Mice were trained to find the platform and assessed on their ability to spatially learn and remember the platform location. Aged p73 +/À mice were significantly impaired in their ability to discriminate the platform location (as measured by percent time in the platform zone) and in the length of time (latency) it took to find the platform ( Figures 1G and 1H ), although they swam at a speed similar to aged p73 +/+ mice ( Figure 1I Figure 2C ). The volume perturbations in motor cortex and cerebellum could explain the aberrant clasping and grip test behaviors, and the dentate gyrus atrophy could explain the poor water maze performance.
To ask about the cellular basis of this atrophy, we analyzed cytoarchitecture of Nissl-stained sections through one affected region, the motor cortex. Measurement of coronal sections at equivalent rostrocaudal levels revealed that width of the motor cortex from corpus callosum to the pia (see boxed region in Figure 2D ) was thinner in aged p73 +/À versus p73 +/+ mice (Figures 2E and 2F) . Neuronal density was also decreased in aged p73 +/À mice ( Figure 2G ). To confirm this, we performed unbiased stereology using the optical fractionator method (Gundersen et al., 1988; West et al., 1996; Luk and Sadikot, 2003; Luk et al., 2001) . The mean coefficient of error (Gundersen and Jensen, 1987) of Nissl-stained neuronal counts was 0.9 ± 0.005 (n = 4). In aged p73 +/À primary motor cortex, there was a reduction (29%) in total neuron number (743,531 ± 83,667 versus 1,054,281 ± 30,512 in aged controls, mean ± SEM, n = 3; p < 0.05) ( Figure 2H ) and in total volumetric density (28%; 129,144 ± 7,967 versus 179,535 ± 12,601 in aged controls; number/mm 3 , mean ± SEM, n = 3; p < 0.05). In contrast, total glial cell number was unchanged ( Figure 2I ). We also observed an increase in density of small, condensed cells in the aged p73 +/À motor cortex ( Figures 2J and 2K ). Some of these expressed the neuronal marker NeuN ( Figure 2L ), but not the astrocytic marker GFAP or the microglial marker Iba1 (data not shown). To ask whether these were dying neurons, we performed silver staining for degenerating cells. This analysis revealed, in aged p73 +/À but not p73 +/+ brains, condensed, silver-stained, degenerating cells, many with dystrophic neurites ( Figure 2M ), identifying them as neurons. There were also many silver-stained neuritic processes ( Figure 2M ). In contrast, young p73 +/À and p73 +/+ brains did not contain degenerating cells (data not shown), and both genotypes were similar with regard to cortical thickness (p > 0.05) and density of neurons and condensed cells (Figures 2G and 2K) . Thus, neuronal degeneration likely accounts for the atrophy of aged p73 +/À brains.
Neurodegenerative disorders like Parkinson's disease and AD also manifest in the PNS (Hawkes, 2006; Goldstein, 2003) . In this regard, we observed that 67% of aged p73
, mice displayed prolapse of the penis and/or rectum (12/21 penis only, 4/21 rectum only, 2/21 both; Figure S1A ). To ask whether this was due to peripheral neurodegeneration, we characterized parasympathetic neurons of the major pelvic ganglion, which innervates the penis. Immunostaining for the parasympathetic marker nNOS and the panneuronal marker PGP9.5 revealed that pelvic ganglia from aged prolapsed p73 +/À mice contained many fewer neurons (Figures S1B and S1C), and those neurons that were present were shrunken. Thus, p73 +/À mice displayed phenotypes arising from degeneration of both the CNS and PNS. Figure 2D ) demonstrated an increase of $3-fold ( Figures 3A and S2A) . Similarly, immunostaining for GFAP showed increased reactive astrocytes in the aged p73 +/À motor cortex ( Figure 3B ). Another hallmark of neurodegeneration is intralysosomal accumulation of the oxidative stress biomarker lipofuscin, a cause of premature dementia in Batten's disease (Seehafer and Pearce, 2006; Haltia et al., 2006) . Lipofuscin autofluorescence was increased throughout aged p73 +/À versus p73 +/+ brains ( Figure S2B ), and quantification demonstrated an $2.5-fold increase in lipofuscin particle size in the aged p73 +/À motor cortex ( Figure 3C ). Thus, normal levels of p73 are necessary to prevent brains from degenerating as they age.
Normal Levels of p73 Are Essential to Prevent Neuronal Cell Cycle Reentry and Cellular Senescence during Aging
One pathological event observed in AD is aberrant re-expression of cell cycle proteins and re-entry of neurons into the cell cycle (Herrup and Yang, 2007) . Since p73 can directly regulate the cell cycle (Talos et al., 2007) , we asked whether this also occurred in aged p73 +/À mice. Immunostaining of forebrain sections revealed a subpopulation of NeuN-positive neurons that aberrantly expressed the cell cycle marker PCNA in the motor cortex and adjacent lateral cortical region of aged p73 +/À but not p73 +/+ mice ( Figure 3D ). To confirm and quantify this result, we isolated cerebral cortices, immunostained the triturated cortical tissue for NeuN, stained with propidium iodide to monitor cell cycle status, and performed flow cytometry, gating for single cells. Approximately 0.8% of wild-type neurons had a DNA content indicative of the G 2 or M phase of the cell cycle ( Figure 3E ), a number that was increased as much as 2-fold with p73 +/À neurons ( Figures   3E and 3F ). In contrast, the percentage of NeuN-negative nonneuronal cells in G2/M phase was similar in both genotypes (p > 0.05). Thus, p73 regulates neuronal cell cycle reentry as mice age. Cellular senescence also occurs as cells and animals age, and the p53 family, including p73, is implicated in regulation of senescence Talos et al., 2007; Papazoglu and Mills, 2007) . We therefore double labeled forebrain sections for NeuN and for a marker of senescing cells, senescence-associated b-galactosidase (SA-b-Gal) (Serrano et al., 1997) . Two populations of SA-b-Gal-positive cells were seen in the aged cortex; NeuNpositive neurons ( Figure 3G ) and NeuN-negative, vasculature-associated cells that were more darkly stained for SA-b-Gal. Quantification revealed a significant increase in the more lightly stained cells in aged p73 +/À versus p73 +/+ motor cortex ( Figures 3H and   3I ). Thus, p73 haploinsufficiency causes increased neuronal expression of a senescence marker as animals age.
Haploinsufficiency for p73 Causes Formation of Aberrant Phosphorylated Tau Filaments in the Aged Brain In humans, high levels of filamentous hyperphosphorylated tau protein are thought to be one of the underlying causes of neurodegeneration (Ballatore et al., 2007) . We therefore immunostained sections from brains of young and aged p73 +/À and p73 +/+ mice with three antibodies that recognize phosphotau-containing paired helical filaments (P-PHF-tau), AT-8 (phospho-Ser202 and phospho-Thr205; Goedert et al., 1995) , AT-180 (phospho-Thr231), and AT-100 (phospho-Ser212 and phosphoThr214). No P-PHF-tau immunoreactivity was observed in brains of young animals or of aged p73 +/+ mice ( Figure 4A ). Unexpectedly, all of the aged p73 +/À brains contained abundant P-PHFtau immunoreactivity, as visualized with the three antibodies ( Figures 4A-4D ). Phosphatase treatment abolished this immunostaining ( Figure S3A ), confirming the labeling specificity. This P-PHF-tau immunoreactivity was localized throughout the brain, including the motor cortex ( Figures 4A-4D ), the hippocampus, the subiculum, ( Figure 4E ), and the piriform cortex (data not shown). P-PHF-tau immunoreactivity was localized within cells and their neuritic processes ( Figures 4A-4E) , and many positive cells coexpressed bIII-tubulin (data not shown), confirming their identity as neurons. P-PHF-tau immunoreactivity was also present within neuropil threads and dystrophic neurites. Quantification within a defined region of the lateral cortex where P-PHF-tau structures were consistently present ( Figure 4F ) demonstrated the specificity of this immunoreactivity for aged, p73 +/À brains ( Figures 4G and 4H ). In contrast, b-amyloidpositive plaques, as detected by thioflavin-T staining, were not present in brains of either genotype (data not shown). Two different approaches confirmed that this staining reflected P-PHF-tau filaments. First, immuno-electron microscopy with AT-8 on aged p73 +/À cortices revealed immunoreactive filaments, either scattered or in bundles, within neuronal cell bodies ( Figure 4I ) and axons ( Figure 4J ). Second, we fractionated p73 +/À versus p73 +/+ brains to enrich for P-PHF-tau filaments (Ikeda et al., 2005) ; western blots confirmed the presence of AT-8-immunopositive P-PHF-tau filaments in these fractions ( Figure S3B ). Thus, p73 haploinsufficiency causes formation of P-PHF-tau tangle-like structures similar to those seen in neurodegenerative disorders. Neuron p73 in Neurodegeneration develop tangles, this only occurs long after plaque formation. Since p73 haploinsufficiency causes both neurodegeneration and P-PHF-tau positive filaments, we asked whether it might be a susceptibility factor for AD. To do this, we crossed p73 +/À mice with the transgenic CRND8 (TgCRND8 +/ø ) mouse model of AD (Chishti et al., 2001) . These mice encode a double-mutant form of APP 695 (KM670/671NL+V717F) under the control of the PrP gene promoter and develop plaques, but not tangles, by 3 months and do not display neuronal loss. We analyzed these crosses at 1.5-2 months, a time point early during plaque formation, first quantifying plaque density by thioflavin T staining and immunocytochemistry with two antibodies, the 4G8 antibody specific for human APP ( Figure 5C ) and the 6E10 human APP 
C-terminal-specific antibody (data not shown).
This analysis demonstrated a small number of plaques in 1.5-to 2-month-old TgCRND8 +/ø brains, regardless of p73 genotype ( Figures 5A-5D ). We then immunostained brains with AT-8 and AT-180 to reveal P-PHF-tau. As reported (Bellucci et al., 2007) , there was no immunoreactivity detected by either antibody in young TgCRND8 +/ø brains ( Figures 5E and 5F ). In contrast, all of the p73 +/À ; TgCRND8 +/ø brains displayed abundant P-PHF-tau filaments/deposits at 1.5-2 months of age ( Figures 5E and 5F ). These P-PHF-tau structures were consistently present in the lateral cortex and, to a lesser degree, in other forebrain regions and in the hippocampus and subiculum ( Figure S4 ). Quantification in the lateral cortex demonstrated the specificity of these P-PHF-tau filaments for the p73 +/À ; TgCRND8 +/ø brains ( Figures 5G and 5H) . Thus, p73 haploinsufficiency and overexpression of mutant APP together cause P-PHF-tau accumulation early during the ADtype neuropathology.
We then asked whether p73 heterozygosity led to neuronal loss in these mice. Stereological analysis, using the optical fractionator method, demonstrated that total primary motor cortex neuron number was reduced by 22% in p73 ; NTg = animals that did not carry the TgCRND8 transgene.
Neuron p73 in Neurodegeneration versus 927,555 ± 25,798, respectively; mean ± SEM, n = 4; p < 0.05) ( Figure 5I ). Silver staining also revealed the presence of degenerating cells, many with dystrophic neurites identifying them as neurons, in the 2-month-old p73 +/À ; TgCRND8 +/ø brains (Figure 5J ). By 12 months of age, this degeneration was even more dramatic ( Figure 5K ), with many condensed, dystrophic neurons present throughout the brain and numerous silver stain-positive neurites ( Figure 5K ). In contrast, only the very occasional silver stain-positive cell was observed in the 12-month-old TgCRND8 +/ø brain, although we did observe silver-stained plaques ( Figure 5K ; data not shown). Thus, p73 haploinsufficiency causes neuronal loss and degeneration coincident with accumulation of P-PHF-tau filaments in an APP-based mouse model of AD.
p73 Modulates JNK Activity to Regulate Neuronal Survival and Tau Phosphorylation Since DNp73 antagonizes proapoptotic p53 family members, one potential explanation for these findings is upregulation of the levels and/or activity of p53 or p63 (Jacobs et al., 2005 (Figures 6A-6C) . A second potential explanation involves JNK, since we previously showed that DNp73 can bind to and inhibit JNK (Lee et al., 2004) , and JNK has been implicated in both neurodegeneration and aberrant tau phosphorylation (reviewed in Johnson and Nakamura, 2007) . We therefore measured JNK activity in cultured p73
, and p73 À/À cortical neurons. Western blot analysis revealed that levels of the phosphorylated, activated form of JNK increased as the number of wild-type p73 alleles decreased ( Figure 6D ). Coincident with this increase in JNK activity, we observed that p73 +/À and p73 À/À cortical neurons were more vulnerable to death in response to mildly excitotoxic concentrations of the neurotransmitter glutamate ( Figures 6E and S5) . Measurement of lactate dehydrogenase (LDH) release into the medium, a biochemical indicator of necrosis, demonstrated that, unexpectedly, LDH release increased as p73 copy number decreased ( Figure 6F ). Thus, decreased p73 copy number causes increased JNK activity and sensitizes neurons to oxidative damage-induced necrosis. Since JNK directly phosphorylates tau on residues known to be hyperphosphorylated in P-PHF-tau (Reynolds et al., 1997 (Reynolds et al., , 2000 Yoshida et al., 2004) , we asked whether JNK dysregulation might also explain the aberrant P-PHF-tau filaments. Western blot analysis revealed increased tau phosphorylation at Ser202/ Thr205, targets of JNK-mediated phosphorylation, in neonatal p73 À/À versus p73 +/+ cortices ( Figure 6G ). To ask whether this tau phosphorylation was JNK dependent, we cultured cortical neurons and treated them for 90 min with the JNK inhibitor SP6000125. SP6000125 decreased phosphorylation of the JNK target, c-jun, confirming the efficacy of the inhibitor ( Figure 6H ). The JNK inhibitor significantly decreased tau phosphorylation in both p73 +/+ and p73 À/À neurons ( Figure 6I ).
These data indicate that loss of p73 causes increased JNK activity and tau phosphorylation in cultured neurons. To ask whether JNK dysregulation might also explain the phenotypes documented here, we performed double-label immunocytochemistry for phospho-JNK and P-PHF-tau in the 2-month-old p73 +/À ; TgCRND8 +/ø cortex. Few phospho-JNK-positive neurons were seen in the TgCRND8 brains at this age, as previously , and p73 À/À cortical neurons (n = 6 per group from three separate experiments) were exposed to glutamate (Glu) for 24 hr and (E) percent survival was calculated (Hoechstpositive nuclei before and after glutamate), and (F) lactate dehydrogenase (LDH) released into the medium was measured. (G) Western blot analysis was performed for phosphorylated tau (P-tau) with the AT-8 antibody in embryonic day 16 p73 +/+ and p73 À/À cortices, and the blot was reprobed with ERK as a loading control.
(H and I) Cultured cortical neurons were treated with JNK inhibitor (SP 6000125, 20 mM for 90 min). JNK activity was assessed by western blot analysis for phosphorylated c-jun (P-cJun) (H). The effects of JNK inhibition on tau phosphorylation were determined by probing similar western blots with the AT-8 antibody (I). In both cases, blots were reprobed for PLC-g. In all panels, WT = p73
. Values indicate mean ± SEM. *p < 0.05, ***p < 0.001.
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reported (Bellucci et al., 2007) . However, the p73 +/À ; TgCRND8 +/ø brains contained many phospho-JNK-positive cells ( Figure 7A ); quantification revealed a 20-fold increase in their density within the lateral cortex ( Figure 7B ). Most of these phospho-JNK-positive cells were also positive for P-PHF-tau Ser202/Thr205 phosphorylation ( Figures 7A-7D) . Similar results were obtained in the aged p73 +/À brains; many more phospho-JNK-positive cells were present in aged p73 +/À versus p73 +/+ cortices ( Figures 7E  and 7F ), and many of these colocalized with P-PHF-tau Ser202/Thr205 ( Figures 7E, 7G, and 7H) . Thus, p73 haploinsufficiency causes increased neuronal JNK activity that likely participates in the genesis of P-PHF-tau pathology.
DISCUSSION
The findings presented here support three major conclusions. First, our data demonstrate that haploinsufficiency for p73 leads to behavioral and anatomical changes indicative of age-related neurodegeneration. Some of these changes, such as increased microglial activation and enhanced lipofuscin, are likely second- ary to neuronal degeneration. However, the neuronal cell loss, increased neuronal senescence, increased reentry of neurons into the cell cycle, and accumulation of P-PHF-tau filaments are all likely to be direct effects of the loss of p73. Second, we demonstrate that p73 haploinsufficiency causes the amyloid-based TgCRND8 AD mouse model to coincidentally develop the three primary pathologies associated with AD-plaques, P-PHF-tau deposits, and neuronal degeneration-at the same early time point. This accumulation of P-PHF-tau deposits is seen as early as 1.5 months, which is much sooner than in either the p73 +/À mice or in the TgCRND8 AD mice, indicating that these two phenotypes synergize. These animals therefore represent a new mouse model for AD. Third, our mechanistic studies indicate that haploinsufficiency for p73 likely causes both neuronal degeneration/loss and P-PHF-tau filament accumulation by directly regulating JNK. These findings, together with recent reports that decreased p73 expression occurs in some cases of AD (Li et al., 2004) and that some individuals show loss of one copy of the genomic locus encompassing the p73 gene (Wong et al., 2007) , suggest that haploinsufficiency for p73 may represent a previously unrecognized susceptibility factor for AD. One surprising result of our study was the occurrence in aged p73 +/À mice of multiple hallmarks of neurodegeneration, including phosphorylated tau tangle-like structures, lipofuscin deposits, activation of microglia, cellular senescence, and aberrant entry of neurons into the cell cycle. Aberrant tau regulation is prominent in dementias such as AD (reviewed in Johnson and Stoothoff, 2004) , and buildup of lipofuscin causes Batten's disease, an inherited disease with premature dementia (reviewed in Haltia et al., 2006) . Microglia likely contribute to neurodegeneration, since immunosuppression decreases tangles and neuronal loss and increases lifespan in mice expressing mutant tau (Yoshiyama et al., 2007) . Reentry of neurons into the cell cycle has been noted in early-stage AD (reviewed in Herrup and Yang, 2007) , and postmitotic neurons forced to reenter the cell cycle die by p53-dependent apoptosis (reviewed in Jacobs et al., 2006) . Cellular senescence is also associated with aging in mammals. While neurons are postmitotic, and senescence involves cell cycle arrest, these two states are not necessarily equivalent, and it is possible that postmitotic neurons directly enter a senescent state as a consequence of accumulated DNA damage. Alternatively, damaged neurons may aberrantly reenter the cell cycle, as observed here, and perhaps it is this population that then enters a senescent state. In either case, these senescent neurons are abnormal and may well contribute to the pathology described here. Thus, aged p73
brains show all of the hallmarks of a neurodegenerative phenotype. How does p73 haploinsufficiency cause neurodegeneration? A characteristic of the aging brain is increased vulnerability to toxic insults such as oxidative stress and the resultant DNA damage. In this regard, we show here that loss of one or two alleles of p73 markedly enhances the vulnerability of CNS neurons to excitotoxicity-induced necrotic cell death, and we have previously shown that overexpression of truncated DNp73 protects neurons from DNA damage-induced apoptosis (Pozniak et al., 2002; Walsh et al., 2004) . We propose that the neurodegeneration phenotypes reported here are the result of reduced DNp73 levels, which is the only detectable p73 isoform in the postnatal mouse CNS (Pozniak et al., 2000) . DNp73 binds to and suppresses the activity of two important regulators of neural death, p53 (Pozniak et al., 2000) and JNK (Lee et al., 2004) , and data presented here indicate that it is the latter pathway that is perturbed in the aged p73 +/À brain. This aberrant JNK activation would sensitize cells to oxidative damage, ultimately causing cell senescence and loss (Yang et al., 1997) . JNK is also a tau kinase (Reynolds et al., 1997 (Reynolds et al., , 2000 Yoshida et al., 2004) , and, as seen here, aberrant upregulation of tau phosphorylation likely causes genesis of P-PHF-tau filaments, which may themselves cause neuronal degeneration.
A second surprising finding of our study is that the combination of p73 haploinsufficiency and overexpression of mutant APP causes neurodegeneration and P-PHF-tau accumulation much earlier than is seen in either genotype alone, suggesting that these two insults synergize. The resultant mouse therefore mimics human AD, demonstrating coincident neuronal loss, and plaque and P-PHF-tau filament formation, without the necessity of tau overexpression. Interestingly, genetic deletion of Pin1, a prolyl isomerase that stabilizes p73, also causes neurodegeneration and accumulation of P-PHF-tau (Liou et al., 2003) . Why do these two genetic alterations together cause an early AD-like phenotype? We propose that p73 haploinsufficiency and b-amyloid accumulation converge to upregulate JNK activity in neurons. This convergent JNK dysregulation would presumably cause early dysregulation of tau phosphorylation and increased sensitivity to the toxic effects of b-amyloid and other oxidative stresses (reviewed in Johnson and Nakamura, 2007) . The net predicted result would be neurodegeneration at time points much earlier than seen with either genetic insult individually, as reported here.
These data, and the recent association between decreased DNp73 and AD (Li et al., 2004) , suggest that those individuals with copy number variations at the p73 genomic locus (Wong et al., 2007 ) may be at enhanced risk for development of AD or other neurodegenerative disorders. We predict that this population would also be more vulnerable to age-related neurodegeneration or other degenerative disorders such as Parkinson's disease. It will be interesting to test this prediction and to determine whether haploinsufficiency for p73 will exacerbate the degeneration phenotype of mouse models of other human diseases.
EXPERIMENTAL PROCEDURES Animals
This study was approved by The Hospital for Sick Children's Animal Care Committee, and use was in accordance with CCAC guidelines. p73 +/À transgenic mice were maintained on a C129SvJae background, as described (Pozniak et al., 2000 (Pozniak et al., , 2002 . TgCRND8 hemizygous mice containing the Swedish (K670N/M671L) and Indiana (V717F) APP mutations were maintained on a C129 background, as described (Chishti et al., 2001 
Primary Neuron Cultures
Embryonic cortical cultures were prepared as described (Lee et al., 2004) . For cell death experiments, 50 mM glutamate was added at 7 DIV, and nuclei were labeled with Hoechst 33258 (1:2000). LDH release was assayed as described (Wetzel et al., 2003) . JNK was inhibited with SP6000125 (AG Scientific, San Diego, CA).
Behavioral Studies
All behavioral testing took place under dim lighting and constant background noise. Mice were handled 4 min a day for 7 days and habituated to the test environment prior to testing. Groups of 15 to 20 mice were tested sequentially and were handled, habituated, trained, and tested at the same time of day for each experiment. Behavioral tests were run in order from least to most stressful, i.e., limb clasping, paw grip endurance, open-field, water maze. Details of behavioral tests are described in Supplemental Data.
Neuroanatomy
For histology, mice were sacrificed by sodium pentobarbital overdose and transcardially perfused with PBS followed by 4% paraformaldehyde. Tissues were cryoprotected and sectioned at 16 mm or 20 mm for brains and penises, respectively. Nissl staining and immunocytochemistry were performed as described (Pozniak et al., 2002) . Endogenous lipofuscin autofluorescence was quenched using Autofluorescence Eliminator (Chemicon, Temecula, CA). Antibodies are listed in Supplemental Data. Immunoreactivity was visualized using CY-3 or FITC conjugated secondary antibodies (1:250, Jackson ImmunoResearch Labs, West Grove, PA) and nuclei labeled with Hoechst 33258 (1:2000, Sigma). SA-b-gal staining was performed as described (Dimri et al., 1994) . To detect argyrophilic, degenerating neurons, silver staining was performed using the FD NeuroSilver kit II (FD Neurotech, Ellicott City, MD). Neuroanatomical parameters were measured in the motor cortex at the same rostrocaudal level and were quantified in a strip of cortical tissue 325 mm wide spanning from corpus callosum to pial surface as shown in Figure 2B . Cell and fluorescence density were calculated using these area, cell count, and fluorescence measurements (Pozniak et al., 2002) . All digital image acquisition was performed using Northern Eclipse software (Empix Inc.) linked to a Sony XC-75CE CCD video camera (Tokyo, Japan), and processed by ImageJ analysis software (National Institute of Health).
Stereology
Total neuron number and volumetric density of primary motor cortex neurons were obtained by applying unbiased stereology using the optical fractionator (Gundersen et al., 1988; West et al., 1996; Luk and Sadikot, 2003; Luk et al., 2001) with Stereo Investigator software (Micobrightfield, VT, USA). The rostral and caudal limits of the primary motor cortex were determined (equivalent to Bregma 2.46 to À1.94 mm; Paxinos and Franklin, 2001) , and every 55th serial section of 16 mm within this volume was examined. Typically, six coronal sections at 880 mm intervals were analyzed throughout the reference volume. Mean section thickness after Cresyl Violet processing, mounting, and coverslipping was 10 mm (tissue shrinkage effect), as measured with a z axis microcator. Sampling of the primary motor cortex was performed by randomly translating a grid with 300 3 300 mm squares onto the section of interest and applying an optical dissector consisting of an 80 3 80 3 6 mm brick. Sections were analyzed by using a 3100 lens (oil, numerical aperture of 1.3, with matching condenser). The most prominent nucleolus was taken as the unique identifier in all sections stained for Nissl substance.
Magnetic Resonance Imaging
For MRI, mice were perfusion fixed, decapitated, and skinned skulls were incubated in ProHance contrasting reagent (Henkelman et al., 2006; Spring et al., 2007) . Prior to imaging, samples were removed from the contrast agent solution, blotted, and placed into 13 mm diameter plastic tubes filled with a proton-free susceptibility-matching fluid (Fluorinert FC-77, 3M Corp., St. Paul, MN). Digital anatomical images of brains within skulls were acquired with a multichannel 7.0 Tesla MRI scanner (Varian Inc., Palo Alto, CA) with a 6 cm inner bore diameter insert gradient set. Three brains were imaged in parallel using custom-built, 14 mm diameter solenoid coils with a length of 18.3 cm and over wound ends. The parameters used in the scans were optimized for gray/white matter contrast: a T2-weighted, 3D fast spin-echo sequence, with TR/TE = 325/32 ms, four averages, field-of-view 12 3 12 3 25 mm, and matrix size = 432 3 432 3 780 giving an image with 32 mm isotropic voxels 35 . Total imaging time was 11.3 hr. Geometric distortion due to position of the three coils inside the magnet was corrected using an MR phantom. An unbiased model-independent atlas of the MR scans was created as previously described (Spring et al., 2007) and detailed in Supplemental Data.
Flow Cytometry of DNA Content
One cortical hemisphere per animal (n = 6 per group) was minced, dissociated with papain (2.5 U/ml, Worthington Biochemicals, Lakewood, NJ), dispase (1 U/ml, Sigma), and DNase I (250 U/ml, Sigma) for 30 min at 37 C, triturated in DMEM containing 10% FBS, and fixed with 70% ethanol. Cells were blocked using the Mouse-on-Mouse (MOM) kit (Vector labs, Burlington, ON, Canada), and immunolabeling was performed with monoclonal mouse antiNeuN (1:100; Chemicon), biotinylated anti-mouse IgG secondary, and Strepavidin conjugated FITC (1:400; Becton Dickson, Mississauga, ON, Canada). Samples were incubated with propidium iodide (50 mg/ml, Sigma) and RNase A (2 mg/ml, Fermentas, Burlington, ON, Canada), and analyzed using a FACScan (Becton Dickinson, Franklin Lakes, NJ) and FlowJo software (Tree Star, Inc., Ashland, Oregon), gating for single cells.
Electron Microscopy
Mice were sacrificed by sodium pentobarbital overdose and transcardially perfused with 4% PFA and 0.1% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4. The tissue was dehydrated, infiltrated with LR White, 80 nm sections were placed on Formvar-coated nickel grids, incubated with P-PHF-tau (AT-8; 1:10), which was detected using goat anti-mouse gold conjugate secondary antibodies (10 nm gold; 1:20, Jackson ImmunoResearch Labs), fixed 10 min with 2% glutaraldehyde, stained with uranyl acetate, and lead citrate. The sections were examined using an FEI Tecnai 20 transmission electron microscope (FEI Company, Hillsboro, OR), and images were captured using a Gatan Dualview digital camera (Gatan Inc, Pleasanton, CA).
Quantitative RT-PCR Total RNA was extracted from each cortex using Trizol reagent (Invitrogen) and the RNeasy kit (QIAGEN). cDNA was prepared with SuperScript III First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen). Real-time PCR was performed according to the manufacturers' specifications using Chromo4 Real-Time PCR Detection System (Bio-Rad) and a Platinum Quantitative PCR SuperMix-UDG (Invitrogen). Samples were analyzed in triplicate and were normalized to b-actin for each reaction. The primers are detailed in Supplemental Data. All PCR products were single bands with predicted molecular weights.
Phosphatase Treatment
To determine specificity of P-PHT-tau antibodies, fixed brain sections were dephosphorylated and then labeled with P-PHF-tau antibody AT-180 as previously described (Papasozomenos and Binder, 1987; Yang et al., 2003) and described in Supplemental Data.
Biochemistry and Western Blot Analysis
Western blot analyses of cultured cortical neurons were performed as previously described (Lee et al., 2004) . Antibodies are in Supplemental Data. To detect P-PHF-tau in aged mouse brain, a P-PHF-tau enriched fraction was generated from 18-month-old p73 +/À and p73 +/+ mice as previously described (Ikeda et al., 2005) .
Statistics
Data are expressed as means ± SEM. Significant differences between means were determined using t tests or one-way analysis of variance.
SUPPLEMENTAL DATA
The Supplemental Data include figures, movies, and Supplemental Experimental Procedures and can be found with this article online at http://www. neuron.org/cgi/content/full/59/5/708/DC1/.
